The U.S. FDA approved Edwards Lifesciences’ SAPIEN 3 transcatheter aortic valve replacement (TAVR) for asymptomatic severe aortic stenosis (AS), based on data from the EARLY TAVR trial. Patients undergoing early TAVR experienced lower rates of death, stroke, or unplanned hospitalization compared to those managed with clinical surveillance, indicating potential benefits of early intervention in this patient population.

Source: Edwards Lifesciences